Holen Sie sich die Stockscreener-App
1.65
35.25%
0.43
Schlusskurs vom Vortag:
$1.22
Offen:
$1.22
24-Stunden-Volumen:
23.79M
Relative Volume:
6.92
Marktkapitalisierung:
$17.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.66M
KGV:
-0.2023
EPS:
-8.156
Netto-Cashflow:
$-11.09M
1W Leistung:
+79.33%
1M Leistung:
+39.83%
6M Leistung:
-24.66%
1J Leistung:
-7.82%
1-Tages-Spanne:
$1.2172
$1.88
1-Wochen-Bereich:
$0.8805
$1.88
52-Wochen-Spanne:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.65 | 13.13M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aug Closing: Is Phio Pharmaceuticals Corp. being accumulated by smart moneyJuly 2025 Reactions & Real-Time Chart Breakout Alerts - mfd.ru
What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Benzinga
Best Penny Stocks To Watch Now – February 10th - Defense World
DealFlow Events Sets Stage for PEIO Stock Momentum - StocksToTrade
Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling - TechStock²
Phio reports positive results from PH-762 skin cancer trial By Investing.com - Investing.com Canada
PHIO: HC Wainwright & Co. Reiterates Buy Rating with $14 Price T - GuruFocus
Phio Pharmaceuticals Corp. (PHIO) stock: jumps 43% as cancer trial shows strong safety and response rates - parameter.io
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Benzinga
DealFlow Conference Set to Boost Over 100 Companies - StocksToTrade
Phio Pharmaceuticals stock soars after strong cancer treatment results By Investing.com - Investing.com South Africa
Phio Pharmaceuticals stock soars after strong cancer treatment results - Investing.com
DealFlow Discovery Conference Unveils Corporate Opportunities - timothysykes.com
Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results - TipRanks
Phio Pharmaceuticals Corp Announces Positive Phase 1b Trial Results for PH-762 - TradingView
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial - TMX Newsfile
Retail Surge: Does Phio Pharmaceuticals Corp offer margin of safety2025 Growth vs Value & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Can Phio Pharmaceuticals Corp. sustain its profitability2025 Momentum Check & Long-Term Growth Portfolio Plans - mfd.ru
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference - TMX Newsfile
Cancer drug developer Phio joins free Atlantic City investor discovery event - stocktitan.net
Aug PreEarnings: Is Hennessy Capital Investment Corp VII stock a top performer YTDJuly 2025 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Phio Pharmaceuticals reports 70% response rate in skin cancer trial By Investing.com - Investing.com India
Phio Reports Positive Phase 1b PH-762 Skin Cancer Data - TipRanks
Phio Pharmaceuticals Corp Announces Key Tumor Response Data from PH-762 Trial - TradingView
Phio Pharmaceuticals reports 70% response rate in skin cancer trial - Investing.com
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial - TMX Newsfile
Is Phio Pharmaceuticals Corp. stock a contrarian buyLong-Term Growth Stocks & Low Risk Trading Plans - Bollywood Helpline
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - TMX Newsfile
Retail Trends: Does Phio Pharmaceuticals Corp offer margin of safetyJuly 2025 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 - TMX Newsfile
Cancer gene-silencing update from Phio at Sidoti virtual conference - Stock Titan
Pullback Watch: How does Phoenix Laser Systems Inc Preferred Security score in quality rankingsBreakout Watch & Fast Gain Swing Alerts - baoquankhu1.vn
Guidance Update: What is the next catalyst for Phio Pharmaceuticals Corp2025 Investor Takeaways & Expert Curated Trade Setups - baoquankhu1.vn
Aug Big Picture: Can Phio Pharmaceuticals Corp stock rebound after recent weaknessWeekly Volume Report & Trade Opportunity Analysis - Bộ Nội Vụ
Market Overview: Is Phio Pharmaceuticals Corp a stock for growth or value investorsMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Trend Recap: How Phio Pharmaceuticals Corp stock reacts to Fed rate cutsQuarterly Performance Summary & High Win Rate Trade Tips - Bộ Nội Vụ
Why Phio Pharmaceuticals Corp. stock is a value investor pickShort Setup & Free Weekly Chart Analysis and Trade Guides - Улправда
Will Phio Pharmaceuticals Corp. stock benefit from infrastructure spendingJuly 2025 Setups & Safe Entry Trade Signal Reports - Улправда
Why retail investors pile into Phio Pharmaceuticals Corp. stock2026 world cup usa national team semifinals defensive leaders low block defense odds analysis insights - Улправда
Insider Buying: Robert Bitterman Acquires Additional Shares of P - GuruFocus
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Momentum Shift: Can Phio Pharmaceuticals Corp stock beat analyst upgradesBuy Signal & Reliable Breakout Forecasts - moha.gov.vn
Best Value Stocks to Buy for April 23rd - MSN
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN
Phio Pharmaceuticals chairman Bitterman buys $5,100 in stock By Investing.com - Investing.com South Africa
Phio Pharmaceuticals chairman Bitterman buys $5,100 in stock - Investing.com
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series - TMX Newsfile
MSN Money - MSN
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - TMX Newsfile
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phio Pharmaceuticals Corp-Aktie (PHIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):